Vimarsana
Biggest News Aggregation in the World

Page 2 - Ralph Stephan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ralph Stephan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ralph Stephan Today - Breaking & Trending Today

Newest MitraClip Iteration Performs Well in the Real World: EXPAND G4 - Vimarsana News

Newest MitraClip Iteration Performs Well in the Real World: EXPAND G4

“This expands the spectrum of the TEER-suitable patients and the formerly untreatable patients,” a researcher says.

Source: tctmd.com
EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL - Vimarsana News

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL

BOSTON, Sept. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary transcatheter... | September 17, 2022

MitraClip G4 Sets the Bar Higher for Transcatheter Edge-to-Edge Repair - Vimarsana News

MitraClip G4 Sets the Bar Higher for Transcatheter Edge-to-Edge Repair

Post-approval study suggests growing pool of TEER-suitable patients

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL - Edwards Lifesciences (NYSE:EW) - Press Release - Vimarsana News

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL - Edwards Lifesciences (NYSE:EW) - Press Release

BOSTON, Sept. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation EW announced results from CLASP IID, the first randomized controlled trial tha

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL - Vimarsana News

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL

/PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced results from CLASP IID, the first randomized controlled trial that directly compares two...